195 related articles for article (PubMed ID: 36333737)
41. Responsiveness of
Alothman SJ; Wang W; Goerlitz DS; Islam M; Zhong X; Kishore A; Azhar RI; Kallakury BV; Furth PA
Cancer Prev Res (Phila); 2017 Apr; 10(4):244-254. PubMed ID: 28283467
[TBL] [Abstract][Full Text] [Related]
42. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
Watson J; Wang T; Ho KL; Feng Y; Mahawan T; Dobbin KK; Zhao S
Breast Cancer Res; 2023 Oct; 25(1):114. PubMed ID: 37789381
[TBL] [Abstract][Full Text] [Related]
43. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Ohta T; Wu W; Koike A; Asakawa H; Koizumi H; Fukuda M
Breast Cancer; 2009; 16(4):268-74. PubMed ID: 19459031
[TBL] [Abstract][Full Text] [Related]
44. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
Shimizu Y; Luk H; Horio D; Miron P; Griswold M; Iglehart D; Hernandez B; Killeen J; ElShamy WM
PLoS One; 2012; 7(4):e34102. PubMed ID: 22511931
[TBL] [Abstract][Full Text] [Related]
45. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
[TBL] [Abstract][Full Text] [Related]
46. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
Stefansson OA; Jonasson JG; Olafsdottir K; Hilmarsdottir H; Olafsdottir G; Esteller M; Johannsson OT; Eyfjord JE
Epigenetics; 2011 May; 6(5):638-49. PubMed ID: 21593597
[TBL] [Abstract][Full Text] [Related]
47. ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Amin R; Morita-Fujimura Y; Tawarayama H; Semba K; Chiba N; Fukumoto M; Ikawa S
Mol Oncol; 2016 Apr; 10(4):575-93. PubMed ID: 26704768
[TBL] [Abstract][Full Text] [Related]
48. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Xu X; Qiao W; Linke SP; Cao L; Li WM; Furth PA; Harris CC; Deng CX
Nat Genet; 2001 Jul; 28(3):266-71. PubMed ID: 11431698
[TBL] [Abstract][Full Text] [Related]
49. Cell fate takes a slug in BRCA1-associated breast cancer.
Lindeman GJ; Visvader JE
Breast Cancer Res; 2011 Apr; 13(2):306. PubMed ID: 21489318
[TBL] [Abstract][Full Text] [Related]
50. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
[TBL] [Abstract][Full Text] [Related]
51. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression.
Cantrell MA; Ebelt ND; Pfefferle AD; Perou CM; Van Den Berg CL
Oncotarget; 2015 May; 6(14):11863-81. PubMed ID: 25970777
[TBL] [Abstract][Full Text] [Related]
52. Somatic structural rearrangements in genetically engineered mouse mammary tumors.
Varela I; Klijn C; Stephens PJ; Mudie LJ; Stebbings L; Galappaththige D; van der Gulden H; Schut E; Klarenbeek S; Campbell PJ; Wessels LF; Stratton MR; Jonkers J; Futreal PA; Adams DJ
Genome Biol; 2010; 11(10):R100. PubMed ID: 20942901
[TBL] [Abstract][Full Text] [Related]
53. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
Warmoes M; Jaspers JE; Pham TV; Piersma SR; Oudgenoeg G; Massink MP; Waisfisz Q; Rottenberg S; Boven E; Jonkers J; Jimenez CR
Mol Cell Proteomics; 2012 Jul; 11(7):M111.013334. PubMed ID: 22366898
[TBL] [Abstract][Full Text] [Related]
54. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
55. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
56. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
57. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.
Shehata M; Teschendorff A; Sharp G; Novcic N; Russell IA; Avril S; Prater M; Eirew P; Caldas C; Watson CJ; Stingl J
Breast Cancer Res; 2012 Oct; 14(5):R134. PubMed ID: 23088371
[TBL] [Abstract][Full Text] [Related]
58. Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.
Barham W; Chen L; Tikhomirov O; Onishko H; Gleaves L; Stricker TP; Blackwell TS; Yull FE
BMC Cancer; 2015 Sep; 15():647. PubMed ID: 26424146
[TBL] [Abstract][Full Text] [Related]
59. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
60. A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.
Pulver EM; Mukherjee C; van de Kamp G; Roobol SJ; Rother MB; van der Gulden H; de Bruijn R; Lattanzio MV; van der Burg E; Drenth AP; Verkaik NS; Hahn K; Klarenbeek S; de Korte-Grimmerink R; van de Ven M; Pritchard CEJ; Huijbers IJ; Xia B; van Gent DC; Essers J; van Attikum H; Ray Chaudhuri A; Bouwman P; Jonkers J
Cancer Res; 2021 Dec; 81(24):6171-6182. PubMed ID: 34548335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
